"モデルナ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonModerna first-quarter revenue jumps on strong overseas COVID vaccine sales - Reuters
- Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales Reuters
- Moderna tops revenue estimates on stronger international COVID vaccine sales Yahoo Finance
- Watch Moderna CEO on Earnings, Flu Shots, Skin Cancer Trials Bloomberg.com
- Moderna Q1 2026 earnings beat on international COVID vaccine sales qz.com
- Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. Barron's
- Moderna (MRNA) Q1 2026 Earnings Transcript The Motley Fool
- Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook Seeking Alpha
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer BioSpace
Article: Moderna sued by CureVac, continuing covid jab maker’s highly eventful start to 2026 - IA...
Article: Moderna sued by CureVac, continuing covid jab maker’s highly eventful start to 2026 IAM Patent
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
Moderna’s first quarter 2026 sales well ahead of estimates The Pharma Letter
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna sees revenue bump from international COVID vaccine sales BioPharma Dive
Moderna beats revenue expectations with $389M, but litigation dogs earnings - BioSpace
Moderna beats revenue expectations with $389M, but litigation dogs earnings BioSpace
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars - StockStory
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars StockStory
Moderna’s Strong Vaccine Sales Outside US Far Surpass Estimates - Bloomberg.com
Moderna’s Strong Vaccine Sales Outside US Far Surpass Estimates Bloomberg.com
Moderna Reports Higher Revenue but Posts a Loss - WSJ
Moderna's Q1 revenues rocket, thanks to ex-US sales - pharmaphorum
Moderna's Q1 revenues rocket, thanks to ex-US sales pharmaphorum
Moderna beats Q1 estimates and reaffirms full-year guidance - Sherwood News
Moderna beats Q1 estimates and reaffirms full-year guidance Sherwood News
Moderna in talks with FDA over post-marketing Covid shot data, with eyes on wider access - Endpoi...
Moderna in talks with FDA over post-marketing Covid shot data, with eyes on wider access Endpoints News
Moderna: Q1 Earnings Snapshot - KING5.com
Moderna: Q1 Earnings Snapshot KING5.com
EU clears Moderna's flu-COVID shot as Q1 loss hits $1.3B - Stock Titan
EU clears Moderna's flu-COVID shot as Q1 loss hits $1.3B Stock Titan
Why Is Moderna Stock Falling Friday? - Moderna (NASDAQ:MRNA) - Benzinga
Why Is Moderna Stock Falling Friday? - Moderna (NASDAQ:MRNA) Benzinga
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates Yahoo Finance
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) Stock Titan
Moderna beats revenue expectations despite wider loss - Investing.com
Moderna beats revenue expectations despite wider loss Investing.com
Moderna stock jumps after Q1 2026 beat (MRNA:NASDAQ) - Seeking Alpha
Moderna stock jumps after Q1 2026 beat (MRNA:NASDAQ) Seeking Alpha
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com
BofA raises Moderna stock price target to $32 on Q1 beat Investing.com
[144] Moderna, Inc. SEC Filing - Stock Titan
[144] Moderna, Inc. SEC Filing Stock Titan
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earni...
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings Proactive financial news
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - Zacks Investment Research
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales Zacks Investment Research
Moderna Q1 2026 slides: revenue surges 260%, litigation weighs - Investing.com
Moderna Q1 2026 slides: revenue surges 260%, litigation weighs Investing.com
Moderna (NASDAQ: MRNA) grows Q1 2026 revenue but books $1.3B loss - Stock Titan
Moderna (NASDAQ: MRNA) grows Q1 2026 revenue but books $1.3B loss Stock Titan
BMS vs. Moderna vs. Pfizer: The RNA Platform Race - Pharmaceutical Executive
BMS vs. Moderna vs. Pfizer: The RNA Platform Race Pharmaceutical Executive
Moderna reports Q1 EPS of $ -3.40 - marketscreener.com
Moderna reports Q1 EPS of $ -3.40 marketscreener.com
Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates - marketscr...
Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates marketscreener.com
Moderna Q1 Earnings Call Highlights - MarketBeat
Moderna Q1 Earnings Call Highlights MarketBeat
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength - ChartMill
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength ChartMill
MRNA Stock Rises Pre-Market: Moderna Bets On US Comeback With Flu Vaccine Pipeline - Stocktwits
MRNA Stock Rises Pre-Market: Moderna Bets On US Comeback With Flu Vaccine Pipeline Stocktwits
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect Yahoo Finance
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Stree...
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimat The Economic Times
Moderna’s combo flu-COVID vaccine receives European authorization - CIDRAP
Moderna’s combo flu-COVID vaccine receives European authorization CIDRAP
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect - StockStory
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect StockStory
Moderna price target raised to $33 from $30 at Morgan Stanley - TipRanks
Moderna price target raised to $33 from $30 at Morgan Stanley TipRanks
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 - Yahoo Finance
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 Yahoo Finance
Moderna Q1 preview: revenue rebound in focus as losses persist (MRNA:NASDAQ) - Seeking Alpha
Moderna Q1 preview: revenue rebound in focus as losses persist (MRNA:NASDAQ) Seeking Alpha
Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL) - marketscreener.com
Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL) marketscreener.com
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates - guardonline.com
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates guardonline.com
Moderna's Q1 revenue at $389M, tops expectations - Breakingthenews.net
Moderna's Q1 revenue at $389M, tops expectations Breakingthenews.net
Moderna price target raised to $32 from $31 at BofA - TipRanks
Moderna price target raised to $32 from $31 at BofA TipRanks
Moderna Up Over 6% in Pre-Market Trading - Moomoo
Moderna developed an mRNA Covid-flu combo vaccine and it’s b... - Kottke.org
Moderna developed an mRNA Covid-flu combo vaccine and it’s b... Kottke.org
Moderna reports Q1 EPS ($3.40), consensus ($3.88) - TipRanks
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss - market...
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss marketscreener.com
Earnings Flash (MRNA) Moderna, Inc. Reports Q1 Revenue $389.0M, vs. FactSet Est of $236.4M - mark...
Earnings Flash (MRNA) Moderna, Inc. Reports Q1 Revenue $389.0M, vs. FactSet Est of $236.4M marketscreener.com
Roivant Sciences: Moderna Settlement, Brepocitinib Support A Long-Term Buy (NASDAQ:ROIV) - Seekin...
Roivant Sciences: Moderna Settlement, Brepocitinib Support A Long-Term Buy (NASDAQ:ROIV) Seeking Alpha
Moderna: Solid Q1 Beat and EU Combo Vaccine Approval Offset by Regulatory Setbacks and Long Path ...
Moderna launches mRNA bird flu vaccine trial after HHS cancels funding - The Washington Post
Moderna launches mRNA bird flu vaccine trial after HHS cancels funding The Washington Post
Moderna (MRNA) Misses Q1 EPS by $1.38, Beats on Revenue - StreetInsider
Moderna (MRNA) Misses Q1 EPS by $1.38, Beats on Revenue StreetInsider
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - BioPharma Dive
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial BioPharma Dive
Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook - marketscreener.com
Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook marketscreener.com
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
Moderna starts late-stage trial of bird flu vaccine in US, UK Reuters
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? Yahoo Finance
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect Zacks Investment Research
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreen...
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates marketscreener.com
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
CureVac sues Moderna for patent infringement over COVID-19 vaccines Reuters
Vanguard Capital Management (MRNA) reports 25.9M-share stake (6.53%) - Stock Titan
Vanguard Capital Management (MRNA) reports 25.9M-share stake (6.53%) Stock Titan
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com India
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com Investing.com India
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
Moderna Stock 5-Day Losing Spree: Stock Falls 18% - Trefis
Why Moderna’s Hot Rally Is Suddenly Cooling - TipRanks
Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story - Yahoo Finance
Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story Yahoo Finance
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Research Analysts Issue Forecasts for Moderna Q1 Earnings MarketBeat
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates - Weatherford ...
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates Weatherford Democrat
Moderna Earnings Notes - Trefis
Moderna Earnings Notes Trefis
Moderna receives EU approval for double vaccine - medwatch.com
Moderna receives EU approval for double vaccine medwatch.com
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EU approval for combined flu, COVID shot for older adults Reuters
Moderna loses key mRNA patent in European vaccine fight - Life Sciences Intellectual Property Review
Moderna loses key mRNA patent in European vaccine fight Life Sciences Intellectual Property Review
Moderna’s H5N1 Vaccine Trial Draws Support As Valuation Stays Stretched - simplywall.st
Moderna’s H5N1 Vaccine Trial Draws Support As Valuation Stays Stretched simplywall.st
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnarou...
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround TechStock²
CureVac targets Moderna with 10-patent suit over Spikevax - Life Sciences Intellectual Property R...
CureVac targets Moderna with 10-patent suit over Spikevax Life Sciences Intellectual Property Review
How a rapid-response bird flu vaccine trial is shaping global preparedness - Gavi, the Vaccine Al...
How a rapid-response bird flu vaccine trial is shaping global preparedness Gavi, the Vaccine Alliance
Earnings call transcript: Moderna Q1 2026 revenue beats expectations By Investing.com - Investing...
Earnings call transcript: Moderna Q1 2026 revenue beats expectations By Investing.com Investing.com Canada
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overha...
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang Yahoo Finance
What Moderna (MRNA)'s Expedited Flu Vaccine Review And Institutional Support Means For Shareholde...
What Moderna (MRNA)'s Expedited Flu Vaccine Review And Institutional Support Means For Shareholders Yahoo Finance
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know Yahoo Finance
F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times
F.D.A. Refuses to Review Moderna Flu Vaccine The New York Times
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says - CNN
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says CNN
Moderna (MRNA) Q1 2026 earnings: revenue beats at $389M - grafa.com
Moderna (MRNA) Q1 2026 earnings: revenue beats at $389M grafa.com
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine The New York Times
Moderna stock surges as FDA reverses course, agrees to review new flu shot - Yahoo Finance
Moderna stock surges as FDA reverses course, agrees to review new flu shot Yahoo Finance
Moderna (MRNA) Stock Jumps 8% After Q1 Earnings Beat - CoinCentral
Moderna (MRNA) Stock Jumps 8% After Q1 Earnings Beat CoinCentral
What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma - MIT Technology Review
What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma MIT Technology Review
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension - Yahoo Finance
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension Yahoo Finance
Europe—not US—first to authorize Moderna’s combo mRNA flu-COVID vaccine - Ars Technica
Europe—not US—first to authorize Moderna’s combo mRNA flu-COVID vaccine Ars Technica
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot BioSpace
FDA Refuses to Review Moderna's Influenza Vaccine for Potential Approval - Contagion Live
FDA Refuses to Review Moderna's Influenza Vaccine for Potential Approval Contagion Live
Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance
Why Moderna (MRNA) Stock Is Trading Up Today Yahoo Finance
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal - CNBC
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal CNBC
FDA reverses course on Moderna flu shot - NPR
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump - Yahoo Finance
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump Yahoo Finance
Moderna’s mRNA Influenza Vaccine Back Under FDA Review - Infectious Disease Advisor
Moderna’s mRNA Influenza Vaccine Back Under FDA Review Infectious Disease Advisor